129 related articles for article (PubMed ID: 11600374)
21. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum.
Rosenthal PJ; McKerrow JH; Aikawa M; Nagasawa H; Leech JH
J Clin Invest; 1988 Nov; 82(5):1560-6. PubMed ID: 3053784
[TBL] [Abstract][Full Text] [Related]
22. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
23. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
[TBL] [Abstract][Full Text] [Related]
24. Modelling of human leucyl aminopeptidases for in silico off target binding analysis of potential Plasmodium falciparum leucine aminopeptidase (PfA-M17) specific inhibitors.
Sahi S; Raj U; Chaudhary M; Nain V
Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(3):191-201. PubMed ID: 25269653
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
Eksi S; Czesny B; van Gemert GJ; Sauerwein RW; Eling W; Williamson KC
Antimicrob Agents Chemother; 2007 Mar; 51(3):1064-70. PubMed ID: 17178799
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease.
Domínguez JN; López S; Charris J; Iarruso L; Lobo G; Semenov A; Olson JE; Rosenthal PJ
J Med Chem; 1997 Aug; 40(17):2726-32. PubMed ID: 9276017
[TBL] [Abstract][Full Text] [Related]
27. Uptake of an antiplasmodial protease inhibitor into Plasmodium falciparum-infected human erythrocytes via a parasite-induced pathway.
Saliba KJ; Kirk K
Mol Biochem Parasitol; 1998 Aug; 94(2):297-301. PubMed ID: 9747980
[No Abstract] [Full Text] [Related]
28. Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum.
Singh A; Rosenthal PJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):949-51. PubMed ID: 11181388
[TBL] [Abstract][Full Text] [Related]
29. Malarial protease inhibitors: potential new chemotherapeutic agents.
Sharma A
Curr Opin Investig Drugs; 2007 Aug; 8(8):642-52. PubMed ID: 17668366
[TBL] [Abstract][Full Text] [Related]
30. Effect of calpain inhibitors on the invasion of human erythrocytes by the parasite Plasmodium falciparum.
Olaya P; Wasserman M
Biochim Biophys Acta; 1991 Apr; 1096(3):217-21. PubMed ID: 2018795
[TBL] [Abstract][Full Text] [Related]
31. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase.
Rosenthal PJ; Wollish WS; Palmer JT; Rasnick D
J Clin Invest; 1991 Nov; 88(5):1467-72. PubMed ID: 1939639
[TBL] [Abstract][Full Text] [Related]
32. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
[TBL] [Abstract][Full Text] [Related]
33. Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases.
Harbut MB; Velmourougane G; Dalal S; Reiss G; Whisstock JC; Onder O; Brisson D; McGowan S; Klemba M; Greenbaum DC
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E526-34. PubMed ID: 21844374
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of fiber cell globulization and hyperglycemia-induced lens opacification by aminopeptidase inhibitor bestatin.
Chandra D; Ramana KV; Wang L; Christensen BN; Bhatnagar A; Srivastava SK
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2285-92. PubMed ID: 12091429
[TBL] [Abstract][Full Text] [Related]
35. Proteases of malaria parasites: new targets for chemotherapy.
Rosenthal PJ
Emerg Infect Dis; 1998; 4(1):49-57. PubMed ID: 9452398
[TBL] [Abstract][Full Text] [Related]
36. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
37. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins.
Xie SC; Dogovski C; Hanssen E; Chiu F; Yang T; Crespo MP; Stafford C; Batinovic S; Teguh S; Charman S; Klonis N; Tilley L
J Cell Sci; 2016 Jan; 129(2):406-16. PubMed ID: 26675237
[TBL] [Abstract][Full Text] [Related]
38. Parasite proteases and antimalarial activities of protease inhibitors.
Vander Jagt DL; Caughey WS; Campos NM; Hunsaker LA; Zanner MA
Prog Clin Biol Res; 1989; 313():105-18. PubMed ID: 2675111
[No Abstract] [Full Text] [Related]
39. The role of Plasmodium falciparum food vacuole plasmepsins.
Liu J; Gluzman IY; Drew ME; Goldberg DE
J Biol Chem; 2005 Jan; 280(2):1432-7. PubMed ID: 15513918
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
Skinner-Adams TS; Andrews KT; Melville L; McCarthy J; Gardiner DL
Antimicrob Agents Chemother; 2007 Feb; 51(2):759-62. PubMed ID: 17088482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
